ZNF181 Inhibitors
ZNF181 inhibitors, while not directly targeting the zinc finger protein ZNF181, can exert their effects by disrupting cellular processes and signaling pathways that ZNF181 is potentially involved in. For instance, LY294002 and Wortmannin both act as PI3K inhibitors, preventing the activation of the AKT pathway, which is a critical regulator of cell survival and metabolism. If ZNF181 is implicated in the regulation of genes downstream of AKT, the inhibition of this pathway would lead to a reduction in the demand for ZNF181's transcriptional activity. Similarly, compounds like Rapamycin, which inhibit mTOR, could reduce the overall need for ZNF181's involvement in cell growth and proliferation-related gene expression by dampening the signals that drive these processes.
Trichostatin A, as an HDAC inhibitor, might interfere with ZNF181's presumed role in chromatin remodeling and gene repression. By increasing histone acetylation and therefore gene expression, it could work against ZNF181's potential repressive function. Proteasome inhibitors like MG132 and Bortezomib may induce a cellular stress response, affecting the stability and function of regulatory proteins including ZNF181. This could result in a decrease in ZNF181's functional activity as the cell attempts to cope with misfolded proteins and disrupted protein turnover.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, it prevents the phosphorylation and activation of AKT, leading to a decrease in nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activity. Reduced NF-κB activity can lead to decreased expression of genes that are potentially regulated by ZNF181 if ZNF181 functions as a transcriptional repressor in the NF-κB signaling pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin specifically inhibits the mammalian target of rapamycin (mTOR), a central cell growth regulator. By inhibiting mTOR, rapamycin can downregulate protein synthesis and cell proliferation. If ZNF181 is involved in these processes, its functional activity can be indirectly decreased as a result of the reduced cellular demand for its regulatory functions. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K. Similar to LY294002, it suppresses AKT activation and downstream signaling pathways including NF-κB. This suppression can result in reduced expression of genes under the control of ZNF181, assuming ZNF181 has a role in these pathways. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase (HDAC) inhibitor. HDACs remove acetyl groups from histones, causing chromatin to become more condensed and less accessible for transcription. By inhibiting HDACs, Trichostatin A can increase gene expression; however, if ZNF181 represses genes by recruiting HDACs, its inhibitory effect would be decreased by Trichostatin A. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. It inhibits the kinase activity of p38 MAPK, which is involved in cellular responses to stress and inflammation. If ZNF181 is a transcriptional regulator that responds to stress signals via the p38 MAPK pathway, SB203580 can indirectly decrease ZNF181's functional activity by inhibiting this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor that blocks the MAPK/ERK pathway. If ZNF181 functions downstream of or is modulated by the MAPK/ERK pathway, inhibition by PD98059 could lead to a decrease in ZNF181's activity within the cell. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). JNK is involved in regulating apoptosis, cell proliferation, and inflammation. If ZNF181 is implicated in these cellular processes via JNK signaling, then SP600125 can lead to a decrease in ZNF181-mediated transcriptional regulation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is another MEK inhibitor that prevents the activation of MAPK/ERK pathway. By doing so, it can reduce the phosphorylation and activation of transcription factors that might be regulated by ZNF181, thereby decreasing ZNF181's functional activity. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 is a proteasome inhibitor that can lead to the accumulation of misfolded or damaged proteins within the cell. If ZNF181 is involved in the cellular stress response to protein accumulation, inhibition of the proteasome by MG132 could indirectly inhibit ZNF181 function by altering stress response signaling. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is another proteasome inhibitor similar to MG132. It can indirectly influence ZNF181 activity by altering the cellular environment, particularly if ZNF181 is involved in the degradation pathway or stress response. | ||||||